Please login to the form below

Not currently logged in


This page shows the latest NASH news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

also working with Ionis on antisense drugs for a range of targets including a nonalcoholic steatohepatitis (NASH) candidate that was the subject of a $300m licensing deal in April.

Latest news

More from news
Approximately 7 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Taking a lean and careful approach Taking a lean and careful approach

    A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what else we can come up with there.”. ... The NASH market is expected to be worth $20bm by 2025 and financial brokers recently valued

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Oncology, immuno-oncology and central nervous system therapies once again topped the charts, but 2016 also saw the emergence of new areas, notably non-alcoholic steatohepatitis or NASH. ... With NASH appearing to be a long-term consequence of obesity it

  • Deal Watch December 2016 Deal Watch December 2016

    The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small molecules in the field of chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, non-alcoholic steato-hepatitis (NASH),

  • Deal Watch September 2016 Deal Watch September 2016

    Taking advantage of the drop in Tobira's market cap following disappointing results from the phase IIb studies in NASH, Allergan still paid a significant amount to secure the business with ... This acquisition brings a phase I oral DPP 4, evogliptin, and

  • Deal Watch April 2016 Deal Watch April 2016

    Nimbus develops Acetyl-CoA Carboxylase (ACC) inhibitors for treatment of liver diseases with the lead compound, NDI-010976 in phase I for non-alcoholic steatohepatitis (NASH - a hot area this month

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....